Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes.

Defining Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL) Based on Survival Outcomes B Background: b DLBCL that fails to achieve a complete response (CR) or relapses early after standard immunochemotherapy (IC, e.g., R-CHOP or similar) is referred to as primary refractory DLBCL (prDLBCL) and has a poor prognosis. Patients with PD had significantly lower CR/PR rates (19.6%/19.6%) to second line therapy compared to patients with EOT PR (32.1%/30.4%) or early relapse (50.6%/19.1%)( I P i < 0.001). [Extracted from the article]